QTTB

Q32 Bio Inc · NASDAQ

Sector Health Technology
Industry Biotechnology
Website q32bio.com
Employees(FY) 37
ISIN US7469641051

Performance

-37.55%

-44.08%

-29.93%

-10.14%

+149.27%

YTD

+173.32%

Profile

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics targeting powerful regulators of the innate and adaptive immune systems to rebalance immunity in autoimmune and inflammatory diseases. Its products in the pipeline include ADX-914, a human anti-IL-7R antibody that re-regulates adaptive immune function, and ADX-097, which has in vivo biodistribution to affected tissues and organs, durable tissue pharmacokinetics and pharmacodynamics, and robust in vivo efficacy. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was incorporated in 2017 and is based in Waltham, Massachusetts.

Advanced Technical Analysis

Technical Analysis of QTTB 2024-11-20

The stock indicators reflect a bearish sentiment, with the Moving Average Score at 10, Oscillators Score at 36, and a Technical Score of 23, indicating overall weakness in the market and suggesting caution for potential investors. The low scores across all categories highlight a lack of bullish momentum and a prevailing downward trend.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of QTTB

Stock Rank

Recent News & Updates

2024-11-07 06:59
Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update(PR Newswire)
2024-11-06 17:59
Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update(Prnewswire)
2024-11-05 06:59
Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference(PR Newswire)
2024-11-04 17:59
Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference(Prnewswire)
2024-10-14 06:59
Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024(PR Newswire)
2024-10-13 18:59
Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024(Prnewswire)
2024-08-29 06:59
Q32 Bio to Participate in Upcoming September Investor Conferences(PR Newswire)
2024-08-28 18:59
Q32 Bio to Participate in Upcoming September Investor Conferences(Prnewswire)
2024-07-09 06:59
Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis(PR Newswire)
2024-07-08 18:59
Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis(Prnewswire)
2024-07-01 06:59
Q32 Bio Joins Russell 3000® Index(PR Newswire)
2024-06-30 18:59
Q32 Bio Joins Russell 3000 Index(Prnewswire)
2024-06-27 07:05
Q32 Bio Inc.'s (NASDAQ:QTTB) last week's 15% decline must have disappointed private equity firms who have a significant stake(Simply Wall St.)
2024-05-09 06:59
Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update(PR Newswire)
2024-05-09 01:56
QTTB Stock Earnings: Q32 Bio Misses EPS for Q1 2024(Investorplace)
2024-05-08 18:59
Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update(Prnewswire)
2024-04-02 19:00
Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer(Prnewswire)
2024-03-18 04:30
Homology Medicines Declares Distribution to Common Stockholders(Globenewswire)
2024-03-15 09:52
FIXX Stock Earnings: Homology Medicines Beats EPS for Q4 2023(Investorplace)
2024-02-29 21:48
Kuehn Law Encourages FIXX, SCTL, EVRI, and GRPH Investors to Contact Law Firm(Globenewswire)
2024-01-26 23:10
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates EGLE, FRLN, ROVR, FIXX(Globenewswire)
2024-01-03 03:08
Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency(Globenewswire)
2023-11-16 17:40
Q32 Bio to merge with Homology Medicines(Pharmaceutical-business-review)
2023-11-15 23:18
Homology enters reverse merger with Q32 Bio(Yahoo Finance)
2023-11-15 18:05
Q32 Bio and Homology Medicines Announce Merger Agreement(Prnewswire)
2023-11-14 04:02
Homology Medicines: Q3 Earnings Snapshot(Yahoo Finance)
2023-11-14 03:33
Homology Medicines Reports Third Quarter 2023 Financial Results(Globenewswire)
2023-08-14 04:20
Homology Medicines: Q2 Earnings Snapshot(Yahoo Finance)
2023-08-14 04:05
Homology Medicines Reports Second Quarter 2023 Financial Results and Recent Highlights(Yahoo Finance)
2023-07-27 04:05
Homology Medicines Announces Plan to Evaluate Strategic Options for the Company and its Genetic Medicines Programs, including HMI-103 Gene Editing Candidate for PKU(Yahoo Finance)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.